AudioCure Pharma

About:

AudioCure is dedicated to the development of drug treatments for hearing disorders with a high unmet medical need.

Website: https://www.audiocure.com

Top Investors: HTGF | High-Tech Gruenderfonds, MED-EL, Jürgen Schumacher

Description:

AudioCure Pharma is a pharmaceutical company with a focus on hearing impairments. Operational since 2012, AudioCure was founded by Professor Hans Rommelspacher; a clinician and academic who has dedicated his career to the discovery and preclinical development of drug candidates. He is joined by highly skilled scientists and executives as well as a tight-knit network of academic partners, internationally renowned advisors and strategic investors. AudioCure is based in Berlin, Germany. Their office is located in a peaceful courtyard in the central area of Mitte. As such, they benefit from being within easy reach of the main train station and many other Berlin high-tech companies and universities while also enjoying the hustle and bustle of this vibrant capital city. They have close ties to the Charité University which allows for a close interaction with the experts of this world renowned institution. Their front-runner compound: AC102, is currently in late stage preclinical development for the treatment of acute noise-induced hearing loss having successfully demonstrated preclinical proof of concept in 2016.

Total Funding Amount:

9M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Berlin, Berlin, Germany

Founded Date:

2010-01-01

Contact Email:

info(AT)audiocure.com

Founders:

Hans Rommelspacher

Number of Employees:

1-10

Last Funding Date:

2016-11-29

IPO Status:

Private

Industries:

© 2025 bioDAO.ai